Racial disparities in the prevalence of cardiovascular disease among incident end-stage renal disease patients

Nephrology Dialysis Transplantation

Volumn 21, Issue 8, 2006, Pages 2202-2209

  Volkova, Nataliya ^a   McClellan, William ^a,b   Soucie, J Michael ^a,b   Schoolwerth, Anton ^c,d  

^a EMORY UNIVERSITY   (United States)

^b End Stage Renal Disease Network 6   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

Coronary heart disease; End stage renal disease; Heart failure; Race

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CAUCASIAN; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; HEART FAILURE; HEMODIALYSIS PATIENT; HUMAN; HYPERTENSION; INCIDENCE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; NEGRO; PREVALENCE; PRIORITY JOURNAL; RACE DIFFERENCE; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SYSTEMATIC ERROR; UNITED STATES;

ADULT; AFRICAN AMERICANS; AGE FACTORS; AGED; CARDIOVASCULAR DISEASES; COMORBIDITY; CORONARY DISEASE; DIABETES MELLITUS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GEORGIA; HEART FAILURE; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; MALE; MEDICARE; MIDDLE AGED; NORTH CAROLINA; OBESITY; ODDS RATIO; PREVALENCE; RENAL DIALYSIS; RETROSPECTIVE STUDIES; SELECTION BIAS; SOUTH CAROLINA;

EID: 33748047461     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfl078     Document Type: Article

References (38)

1. Levey AS, Beto JA, Coronado BE et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis 1998; 32: 853-906
2. Sarnak MJ, Levey AS, Schoolwerth AC et al. Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension 2003; 42: 1050-1065
3. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: The HOPE randomized trial. Ann Intern Med 2001; 134: 629-636
4. Muntner P, He J, Hamm L, Loria C, Whelton PK. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol 2002; 13: 745-753
5. Shlipak MG, Fried LF, Cushman M et al. Cardiovascular mortality risk in chronic kidney disease: Comparison of traditional and novel risk factors. Jama 2005; 293: 1737-1745
6. Weiner DE, Tighiouart H, Amin MG et al. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: A pooled analysis of community-based studies. J Am Soc Nephrol 2004; 15: 1307-1315
7. Weiner DE, Tighiouart H, Stark PC et al. Kidney disease as a risk factor for recurrent cardiovascular disease and mortality. Am J Kidney Dis 2004; 44: 198-206
8. U.S. Renal Data System, USRDS 2003 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Healths, National Institute of Diabetes and Digestive and Kidney Diseases. Bethesda, MD, 2003: 64-65
9. Longenecker JC, Coresh J, Klag MJ et al. Validation of comorbid conditions on the end-stage renal disease medical evidence report: The CHOICE study. Choices for Healthy Outcomes in Caring for ESRD. J Am Soc Nephrol 2000; 11: 520-529
10. Stack AG, Bloembergen WE. Prevalence and clinical correlates of coronary artery disease among new dialysis patients in the United States: A cross-sectional study. J Am Soc Nephrol 2001; 12: 1516-1523
11. Cheung AK, Sarnak MJ, Yan G et al. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int 2000; 58: 353-362
12. Young BA, Maynard C, Boyko EJ. Racial differences in diabetic nephropathy, cardiovascular disease, and mortality in a national population of veterans. Diabetes Care 2003; 26: 2392-2399
13. American Heart Association. Heart Disease and Stroke Statistics - 2004 Update. http://www.americanheart.org/downloadable/heart/ 1079736729696HDSStats2OO4UpdateREV3-1904.pdf. Accessed on 04/19/04
14. Ford ES, Giles WH, Croft JB. Prevalence of nonfatal coronary heart disease among American adults. Am Heart J 2000; 139: 371-377
15. Gillum RF, Mussolino ME, Madans JH. Coronary heart disease incidence and survival in African-American women and men. The NHANES I epidemiologic follow-up study. Ann Intern Med 1997; 127: 111-118
16. McGee D, Cooper R, Liao Y, Durazo-Arvizu R. Patterns of comorbidity and mortality risk in blacks and whites. Ann Epidemiol 1996; 6: 381-385
17. Statistical Analysis System. Version 8.2. SAS Institute, Inc. Cary, NC, USA, 1999
18. Sundquist J, Winkleby MA, Pudaric S. Cardiovascular disease risk factors among older black, Mexican-American, and white women and men: An analysis of NHANES III, 1988-1994. Third National Health and Nutrition Examination Survey. J Am Geriatr Soc 2001; 49: 109-116
19. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. Jama 2003; 290: 199-206
20. Burt VL, Whelton P, Roccella EJ et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension 1995; 25: 305-313
21. Cooper RS, Liao Y, Rotimi C. Is hypertension more severe among U.S. blacks, or is severe hypertension more common? Ann Epidemiol 1996; 6: 173-180
22. Robbins JM, Vaccarino V, Zhang H, Kasl SV. Excess type 2 diabetes in African-American women and men aged 40-74 and socioeconomic status: evidence from the Third National Health and Nutrition Examination Survey. J Epidemiol Community Health 2000; 54: 839-845
23. Harris MI, Flegal KM, Cowie CC et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 1998; 21: 518-524
24. Harris MI, Eastman RC, Cowie CC, Flegal KM, Eberhardt MS. Racial and ethnic differences in glycemic control of adults with type 2 diabetes. Diabetes Care 1999; 22: 403-408
25. Nelson JJ, Liao D, Sharrett AR et al. Serum albumin level as a predictor of incident coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) study. 2000; 151: 468-477
26. Jurkovitz CT, Abramson JL, Vaccarino LV, Weintraub WS, McClellan WM. Association of high serum creatinine and anemia increases the risk of coronary events: Results from the prospective community-based atherosclerosis risk in communities (ARIC) study. J Am Soc Nephrol 2003 14: 2919-2925
27. Sarnak MJ. Cardiovascular complications in chronic kidney disease. Am J Kidney Dis 2003; 41: 11-17
28. Sarnak MJ, Tighiouart H, Manjunath G et al. Anemia as a risk factor for cardiovascular disease in The Atherosclerosis Risk in Communities (ARIC) study. J Am Coll Cardiol 2002; 40: 27-33
29. Hsu CY, Lin F, Vittinghoff E, Shlipak MG. Racial differences in the progression from chronic renal insufficiency to end-stage renal disease in the United States. J Am Soc Nephrol 2003; 14: 2902-2907
30. Smith GL, Shlipak MG, Havranek EP et al. Race and renal impairment in heart failure: Mortality in blacks versus whites. Circulation 2005; 111: 1270-1277
31. Newsome BB, McClellan WM, Allison JJ, Warnock DG. Abstract: Racial differences in survival after acute myocardial infarction according to kidney function. J Clin Invest 2005; 53: S329
32. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med 2000; 342: 1350-1358
33. Bottinger EP, Bitzer M. TGF-beta signaling in renal disease. J Am Soc Nephrol 2002; 13: 2600-2610
34. August P, Suthanthiran M. Transforming growth factor beta and progression of renal disease. Kidney Int Suppl 2003; 87: S99-S1O4
35. Suthanthiran M, Khanna A, Cukran D et al. Transforming growth factor-beta 1 hyperexpression in African American end-stage renal disease patients. Kidney Int 1998; 53: 639-644
36. Suthanthiran M, Li B, Song JO et al. Transforming growth factor-beta 1 hyperexpression in African-American hypertensives: A novel mediator of hypertension and/or target organ damage. Proc Natl Acad Sci USA 2000; 97: 3479-3484
37. Grainger DJ, Witchell CM, Metcalfe JC. Tamoxifen elevates transforming growth factor-beta and suppresses diet-induced formation of lipid lesions in mouse aorta. Nat Med 1995; 1: 1067-1073
38. McCaffrey TA, Du B, Fu C et al. The expression of TGF-beta receptors in human atherosclerosis: Evidence for acquired resistance to apoptosis due to receptor imbalance. J Mol Cell Cardiol 1999; 31: 1627-1642